Clinical bottom line
Long COVID presents a complex challenge in managing patients with chronic infectious diseases, as its multisystem manifestations may overlap or exacerbate underlying conditions. Emerging evidence highlights the need for heightened vigilance for post-acute sequelae in these patients, particularly involving rheumatologic, neurological, and endocrine systems. Clinicians should consider long COVID in differential diagnoses when chronic symptoms persist or worsen, and tailor management plans accordingly. However, diagnostic criteria remain evolving, and therapeutic strategies are largely supportive and symptom-driven at present.
What the evidence shows
Long COVID, characterized by persistent symptoms beyond the acute phase of SARS-CoV-2 infection, can involve diverse organ systems relevant to chronic infectious disease management. Calabrese et al. (2022) emphasize that rheumatologic manifestations such as arthralgia, myalgia, and fatigue may mimic or aggravate autoimmune or inflammatory conditions, complicating clinical assessment and treatment decisions. Similarly, Hein et al. (2025) describe immunomodulatory mechanisms underlying neurological symptoms in long COVID, including cognitive impairment and neuropathic pain, which may overlap with neuroinflammatory sequelae seen in chronic infections.
Endocrine dysfunction, particularly thyroid abnormalities, has been increasingly reported post-COVID-19. Syal et al. (2024) review clinical studies indicating that thyroiditis and altered thyroid hormone levels can persist, potentially impacting metabolic control in patients with chronic infectious diseases who are already vulnerable to endocrine disturbances.
The interplay between long COVID and chronic kidney disease (CKD) is also relevant. Although direct evidence linking long COVID to CKD progression is limited, Warnock et al. (2012) provide foundational insights into managing chronic kidney disease patients, underscoring the importance of monitoring for new or worsening systemic symptoms that could be attributable to post-viral syndromes.
Kouhpayeh et al. (2022) identify clinical features predicting COVID-19 mortality risk, which may inform risk stratification for chronic infectious disease patients during acute infection and potentially influence long-term outcomes, including the risk of developing long COVID.
Smith et al. (2023) contextualize long COVID within the broader framework of infectious causes of chronic disease, drawing parallels with conditions like brucellosis, and advocate for integrated approaches to diagnosis and management that consider the chronicity and complexity of post-infectious syndromes.
Al-Tawfiq et al. (2020) highlight the challenges in balancing care for COVID-19 and non-COVID-19 patients during the pandemic, a consideration that remains pertinent as long COVID adds complexity to chronic infectious disease management.
Caveats and uncertainty
The pathophysiology of long COVID remains incompletely understood, and its diagnostic criteria are not yet standardized, leading to potential misclassification or under-recognition in patients with pre-existing chronic infections. The heterogeneity of symptoms and overlap with other chronic conditions complicate causal attribution. Most evidence derives from observational studies and case series, limiting the ability to infer causality or predict individual patient trajectories.
Therapeutic interventions specific to long COVID are not well established; current management is largely supportive and symptom-based. The impact of long COVID on the natural history of chronic infectious diseases, including potential interactions with ongoing treatments, requires further investigation.
Additionally, many studies have limited follow-up duration and may not capture the full spectrum or duration of long COVID manifestations. The influence of viral variants, vaccination status, and reinfections on long COVID risk and severity in this patient population remains to be elucidated.
How this may change practice
Clinicians managing chronic infectious disease patients should maintain a high index of suspicion for long COVID when evaluating persistent or new symptoms post-SARS-CoV-2 infection. Incorporating screening for rheumatologic, neurological, and endocrine sequelae may facilitate earlier identification and tailored supportive care.
Multidisciplinary collaboration, including rheumatology, neurology, and endocrinology consultation, may be beneficial for complex cases. Monitoring for functional impairment and quality of life changes is important to guide rehabilitation and psychosocial support.
Given the evolving evidence base, clinicians should stay informed about emerging diagnostic criteria and therapeutic guidelines for long COVID. Patient education regarding symptom recognition and the potential for prolonged recovery is essential.
Healthcare systems should consider resource allocation to support integrated care pathways addressing both chronic infectious diseases and post-COVID sequelae, balancing ongoing pandemic demands with routine chronic disease management.